Access to this article is restricted until 12 months after publication by request of the publisher.. Restriction lift date: 2017-06-02
A small molecule activator of p300/CBP histone acetyltransferase promotes survival and neurite growth in a cellular model of Parkinson’s disease
Loading...
Files
Accepted Version
Date
2016-06-02
Authors
Hegarty, Shane V.
O'Leary, Eimear
Solger, Franziska
Stanicka, Joanna
Sullivan, Aideen M.
O'Keeffe, Gerard W.
Journal Title
Journal ISSN
Volume Title
Publisher
Springer International Publishing
Published Version
Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disease characterised by motor and non-motor symptoms, resulting from the degeneration of nigrostriatal dopaminergic neurons and peripheral autonomic neurons. Given the limited success of neurotrophic factors in clinical trials, there is a need to identify new small molecule drugs and drug targets to develop novel therapeutic strategies to protect all neurons that degenerate in PD. Epigenetic dysregulation has been implicated in neurodegenerative disorders, while targeting histone acetylation is a promising therapeutic avenue for PD. We and others have demonstrated that histone deacetylase inhibitors have neurotrophic effects in experimental models of PD. Activators of histone acetyltransferases (HAT) provide an alternative approach for the selective activation of gene expression, however little is known about the potential of HAT activators as drug therapies for PD. To explore this potential, the present study investigated the neurotrophic effects of CTPB (N-(4-chloro-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide), which is a potent small molecule activator of the histone acetyltransferase p300/CBP, in the SH-SY5Y neuronal cell line. We report that CTPB promoted the survival and neurite growth of the SH-SY5Y cells, and also protected these cells from cell death induced by the neurotoxin 6-hydroxydopamine. This study is the first to investigate the phenotypic effects of the HAT activator CTPB, and to demonstrate that p300/CBP HAT activation has neurotrophic effects in a cellular model of PD.
Description
Keywords
Parkinson’s disease , Neurotrophic therapy , Epigenetic regulation , p300/CBP histone acetyltransferase , CTPB , Neuronal survival and growth
Citation
Hegarty, S.V., O’Leary, E., Solger, F., Stanicka, J., Sullivan, A.M. and O’Keeffe, G.W. (2016) 'A small molecule activator of p300/CBP histone acetyltransferase promotes survival and neurite growth in a cellular model of Parkinson’s disease', Neurotoxicity Research, 30(3) pp.510-520. doi:10.1007/s12640-016-9636-2
Collections
Copyright
© 2016, Springer Science+Business Media, New York. The final publication is available at Springer via http://dx.doi.org/10.1007/s12640-016-9636-2